Table 2:
Summary of clinical assessments across all groups for the New Mexico sample.
| PSD (N = 150) | SP (N = 93) | SA (N = 15) | BP-I (N = 42) | ||
|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | p value | |
| Clinical Measures | |||||
| Age of onset (years) | 20.59 (6.01) | 21.31 (5.81) | 20.07 (8.00) | 19.19 (5.51) | p = 0.155 |
| Illness duration (years) | 11.72 (9.17) | 10.19 (8.35) | 12.47 (9.30) | 14.83 (10.22) | p = 0.022 |
| PANSS positive | 14.03 (5.67) | 15.02 (5.86) | 15.20 (5.29) | 11.43 (4.55) | p = 0.002 |
| PANSS negative | 13.78 (5.36) | 15.22 (5.71) | 11.67 (3.74) | 11.36 (3.75) | p < 0.001 |
| PANSS total | 54.43 (15.49) | 58.37 (16.24) | 53.47 (12.98) | 46.07 (10.77) | p < 0.001 |
| CGI | 3.52 (0.91) | 3.74 (0.90) | 3.53 (0.52) | 3.02 (0.87) | p < 0.001 |
| MADRS | 8.44 (7.09) | 9.48 (7.08) | 9.53 (8.80) | 5.74 (5.78) | p = 0.014 |
| YMRS | 4.31 (6.36) | 3.67 (6.07) | 5.80 (5.06) | 5.19 (7.27) | p = 0.276 |
| SBS | 5.80 (2.89) | 7.58 (1.51) | 5.47 (1.13) | 1.98 (1.59) | p < 0.001 |
| Olanzapine equivalent | 12.49 (10.29) | 14.40 (9.67) | 14.54 (16.28) | 7.54 (7.03) | p = 0.001 |
| Extrapyramidal Symptoms | |||||
| AIMS | 0.72 (1.34) | 0.64 (1.07) | 1.40 (1.99) | 0.64 (1.53) | p = 0.112 |
| BAS | 0.53 (1.19) | 0.46 (1.04) | 1.07 (1.75) | 0.48 (1.23) | p = 0.178 |
| SAS | 0.99 (1.83) | 1.07 (1.90) | 1.13 (1.60) | 0.76 (1.75) | p = 0.639 |
Notes: PSD = Psychotic Spectrum Disorders; SP = Patients with schizophrenia; SA = Patients with schizoaffective disorder; BP-I = Patients with bipolar disorder, Type I; AIMS = Abnormal Involuntary Movement Scale (average total for the first 7 variables); BAS = Barnes Akathisia Scale; SAS = Simpson Angus Scale; PANSS = Positive and Negative Syndrome Scale; CGI = Clinical Global Impressions Scale; MADRS = Montgomery and Asberg Depression Rating Scale; YMRS = Young Mania Rating Scale; SBS = Schizo-Bipolar Scale. All p-values derived from sub-group comparisons.